CeriBell’s (NASDAQ:CBLL) Lock-Up Period To Expire on April 9th

CeriBell’s (NASDAQ:CBLL) lock-up period will expire on Wednesday, April 9th. CeriBell had issued 10,606,060 shares in its public offering on October 11th. The total size of the offering was $180,303,020 based on an initial share price of $17.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Canaccord Genuity Group reissued a “buy” rating and set a $33.00 price target on shares of CeriBell in a report on Wednesday, February 26th. TD Cowen lifted their target price on CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $32.60.

CeriBell Trading Down 2.3 %

Shares of NASDAQ:CBLL opened at $18.77 on Wednesday. CeriBell has a fifty-two week low of $18.50 and a fifty-two week high of $32.75. The company has a 50-day moving average price of $22.21.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million during the quarter, compared to the consensus estimate of $17.55 million. On average, equities analysts predict that CeriBell will post -2.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CeriBell

Hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc acquired a new position in shares of CeriBell during the 4th quarter worth $32,000. Summit Investment Advisors Inc. purchased a new stake in CeriBell during the fourth quarter worth about $33,000. Tower Research Capital LLC TRC acquired a new position in CeriBell during the fourth quarter worth about $37,000. BNP Paribas Financial Markets purchased a new position in CeriBell in the fourth quarter valued at about $43,000. Finally, PNC Financial Services Group Inc. acquired a new stake in shares of CeriBell during the 4th quarter valued at approximately $47,000.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.